StockData
Neurogene Inc. logo

Neurogene Inc. (NGNE) stock

NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$23.10−0.20 (-0.86%)

Close on Nov 17, 2026Market cap $462.26MP/E –Yield –

Neurogene price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Neurogene's price to sales ratio was 240.9× on Apr 30, 2025.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Apr 30, 2025240.9×+230.8
2019Apr 30, 201910.1×–

More Neurogene figures

See a number that looks wrong?